IOP-lowering drugs

PSLT shows promise in lowering intraocular pressure Compared with SLT, PSLT appears to offer some advantages, such as a shorter duration of treatment and more comfort for patients.
Nitric oxide: A potential target for glaucoma treatmentEvidence suggests that nitric oxide can modify both mechanical and vascular events in primary open-angle glaucoma pathogenesis.
Combination glaucoma therapy by drug-eluting lensesIn this article, the authors present their recent findings on drug-eluting, extended-wear contact lenses for glaucoma and discuss how these lenses may provide week-long IOP reduction with just one day of wear.
First-in-class glaucoma therapy shows promise in phase II studyTopical AR-13324 0.02% (Rhopressa, Aerie Pharmaceuticals) significantly lowered IOP in eyes with ocular hypertension or open-angle glaucoma in a 28-day phase II study.
Brinzolamide/brimonidine demonstrates broad efficacy in subgroup analysesThe protocols for the pivotal trials establishing the efficacy of the brinzolamide 1%/brimonidine 0.2% fixed combination included pre-planned analyses of subgroups defined by IOP and demographic characteristics.